<?xml version="1.0" encoding="UTF-8"?>
<p id="para0020">Safety testing revealed that T-705 is teratogenic and embryotoxic at concentrations close to the approved human dose.
 <xref rid="bib0099" ref-type="bibr">
  <sup>99</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0102" ref-type="bibr">
  <sup>102</sup>
 </xref> Although conditionally licensed in Japan for the treatment of pathogenic influenza viruses resistant to other therapeutics, these safety concerns prevent drug administration to some high-risk groups such as children or pregnant women.
 <xref rid="bib0103" ref-type="bibr">
  <sup>103</sup>
 </xref> Activity assessment against other potential viral targets in animal models furthermore revealed that in vivo efficacy is quite poor and dependent on extremely high dose concentrations.
 <xref rid="bib0104" ref-type="bibr">
  <sup>104</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0105" ref-type="bibr">
  <sup>105</sup>
 </xref> These results lower the clinical value of T-705 and undermine its use against viruses predominantly associated with pediatric diseases, such as pathogens of the pneumovirus and paramyxovirus families.
</p>
